Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study

Area of Science:

• Genomics
• Pharmacology
• Pediatric Neurology

Background:

• Valproic acid (VPA) is a widely used anticonvulsant.
• VPA exhibits various systemic effects.
• Understanding VPA's molecular mechanisms is crucial for epilepsy treatment.

Purpose of the Study:

• To investigate the blood genomic expression patterns associated with VPA therapy in pediatric epilepsy patients.
• To explore the relationship between VPA efficacy and gene expression profiles.
• To identify potential biomarkers for VPA response.

Main Methods:

• Oligonucleotide microarrays were employed to analyze gene expression in whole blood.
• Gene expression was compared between pediatric epilepsy patients on VPA and drug-free patients.
• Analysis included patients achieving seizure freedom and those with ongoing seizures.

Main Results:

• Treatment with VPA altered the expression of 461 genes compared to drug-free controls.
• A significant downregulation of serine threonine kinases was observed in VPA-treated patients.
• Seizure-free patients on VPA showed 434 upregulated genes, many related to mitochondria, compared to those with persistent seizures or drug-free.

Conclusions:

• Valproic acid therapy is linked to distinct blood gene expression profiles.
• A separate genomic signature correlates with seizure freedom in pediatric epilepsy.
• These findings offer novel insights into the anticonvulsant mechanisms of VPA.